Organization
Guangdong Academy of Medical Sciences
5 abstracts
Abstract
An MRI-based multi-parameter clinical decision support system (NeoMDSS) for early prediction of pathological complete response after the first cycle of neoadjuvant therapy in breast cancer: A multi-center prospective observational cohort study.Org: Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangdong Academy of Medical Sciences, Southern Medical University, Department of Vascular Surgery,
Abstract
Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study.Org: Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,
Abstract
Influence of CD47 on CD8+ T-cell and tumor prognosis based on pan-cancer analysis.Org: Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou University of Chinese Medicine, Southern Medical University,
Abstract
Radiation-sensitive genetic prognostic model to identify individuals at risk for radiation resistance in head and neck squamous cell carcinoma.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Cancer Hospital of Nanchang University, Jiangxi Key Laboratory of Translational Cancer Research, Jiangxi Cancer Hospital of Nanchang University, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
A phase Ⅰ/Ⅱa study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: Results of the CEFRU study.Org: Traditional Chinese Medicine Hospital of Guangdong Province, Guangzhou JOYO Pharma, China National Biotec Group, Guangdong Provincial Hospital of Chinese Medicine Breast Center, Guangdong Provincial People's Hospital,